Showing results (201-210 of 214) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Blood|September 7, 2017
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Heiko Schöder, Somali Gavane, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphomaConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|February 11, 2022
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphomaFushen Sha, Michelle Okwali, Anna Alperovich, et al.
Leukemia & Lymphoma|April 2, 2020
The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patientsRichard J Lin, Laure Michaud, Stephanie M Lobaugh, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
Pageof 22